Do you have the same question? Follow this Question
May 13, 2026 - 08:36 AM
We’ve provided several answers to questions related to Survodutide , see some other helpful Q&A related to this product.
Question: How is this product administered in clinical trials?
Answer: It is administered subcutaneously once weekly, typically with a dose-escalation phase to minimize gastrointestinal side effects, followed by a maintenance phase. The dose-escalation phase is valuable because it helps patients adjust gradually and reduce the risk of side effects.
Question: What is the bioavailability of this product?
Answer: The bioavailability is about 55% when administered subcutaneously. Bioavailability refers to the proportion of the drug that enters circulation and can have an active effect, which is valuable for understanding dosing effectiveness.
View all Survodutide Questions & Answers
